Women are increasingly becoming a significant force in medicine, with their proportion rising from 26% in 2004 to 38% in 2022. 1 This trend extends across all medical subspecialties, with female ...

Breast cancer is the most common cancer diagnosed in women, making it the second most commonly diagnosed cancer in the world. 1,2 About 2.3 million new breast cancer cases and 685,000 deaths occurred ...

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

The choice of wound closure modality after limb-sparing extremity soft-tissue sarcoma (eSTS) resection is fraught with uncertainty. Leveraging machine learning and clinicoradiomic data, we developed ...

The National Cancer Institute defines rare cancer as a cancer with an incidence rate <15 per 100,000 people; recently, the term “ultra-rare cancer” was defined as cancer with an incidence rate <1 × 10 ...

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human ...

Transcript. Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational ...

Patients with advanced melanoma resistant to immune checkpoint or BRAF/MEK inhibitors have treatment options with relatively low efficacy. Lifileucel, a one-time autologous tumor-infiltrating ...

The registry was designed as a pilot study of a web-based interactive platform created and supervised by investigators Memorial Sloan Kettering (MSK) and designed by experts in Web creativity at ...

Mean age was 68 (59-77) years and median follow-up was 74.6 weeks (11.3-195.3). Seven had pSCC and six had PUC. Treatment and surveillance schedules were variable, but generally, patients had ctDNA ...

The two strategies are complementary and, when combined, can accelerate the control of cervical cancer 3: (1) HPV vaccination for long-term and perhaps lifelong cervical cancer risk reduction by ...

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ...